A retrospective single center study was performed on 516 trephine biopsies derived from 160 patients with stable phase Ph + -CML and allogeneic BMT. Following morphometric quantification of reticulin-collagen fibers we tried to elucidate (1) the dynamics of bone marrow fibrosis in the post-transplant period; and (2) the influence of manifest myelofibrosis on relevant engraftment parameters. An evaluation of fiber density at standardized endpoints after BMT was carried out on a selected cohort of 124 patients (399 biopsy specimens). A manifest myelofibrosis (more than a three-fold increase compared to the normal fiber content) before BMT was found in 26% of our patients. Concentrating on bone marrow areas with reconstituting hematopoiesis, several findings emerged. Pretransplant myelofibrosis was associated with an initial regression following BMT, but insidiously recurred in the areas of regenerating hematopoiesis or developed in a few patients without increased pregraft fibers during the post-transplant period (mean observation time more than 4 months). Severe acute GVHD (grades III and IV) was significantly correlated with a greater amount of reticulin fibers in the early post-transplant period (9 to 30 days after BMT). Regarding engraftment parameters, a significant delay was detectable in the time to achieve transfusion independence for the patients with manifest myelofibrosis compared to those without pretransplant fiber increase. Bone Marrow Transplantation (2000) 26, 275-281.
speculation seems to be reasonable, a number of case reports and clinical studies suggest that myelofibrosis per se is not a significant risk factor for delayed hematopoietic reconstitution or graft failure. This is apparent when considering the results of bone marrow transplantation (BMT) in acute (malignant) myelosclerosis [2] [3] [4] [5] or allogeneic BMT and stem cell transplantation in idiopathic (primary) and post-polycythemic myelofibrosis-agnogenic myeloid metaplasia. [6] [7] [8] [9] [10] [11] On the other hand, a conflict of opinion still persists as to whether severe marrow fibrosis may exert an adverse effect on hematopoietic recovery in chronic myelogenous leukemia (CML) following marrow-ablative radiochemotherapy and allogeneic BMT of HLA-matched unrelated or sibling donors. 1, 12 In this context, a number of caveats have to be kept in mind. In addition to a more stringent selection of patients, the bias of cohorts derived from different institutions including variable pre-and posttransplant regimens, and finally a proper diagnosis and accurate grading of myelofibrosis at the microscopic level has to be taken into account. Until now fiber content of the bone marrow has usually been assessed by rather crude semiquantitative grading systems using different scores, 13 especially in CML. [14] [15] [16] Moreover, dynamics of bone marrow fibrosis during pretransplant therapy and after BMT have rarely been followed by performing sequential biopsies on a sufficient number of patients. 17 The purpose of this study was to analyze a large series of CML patients derived from one transplantation center according to (1) the dynamics of bone marrow fibrosis after myeloablative therapy and allogeneic BMT; and (2) the influence of manifest myelofibrosis on engraftment. For this reason, we have examined 516 trephine biopsies of the bone marrow derived from 160 patients with CML at various standardized endpoints by elaborate morphometric methods to determine the density of argyrophilic (reticulincollagen) fibers with regard to hematopoietic reconstitution.
Patients and methods

Ethics
Approval for this study was obtained from the Institutional Review Board on Medical Ethics at the Essen University Hospital.
Patients
Between May 1992 and December 1995 a total of 160 consecutively recruited patients (median age 36.5 years, range 15 to 57 years) with Ph + -CML in first chronic phase underwent allogeneic BMT. The median interval from diagnosis to BMT was 26.4 months (range 5 to 135 months). The marrow cell dose consisted of an unmanipulated graft size of 2.3 × 10 8 /kg nucleated cells (range 0.5-12.7 × 10 8 /kg). The median donor age was 37 years (range 11 to 67 years). Details of pretransplant chemo-and interferon therapy, marrow transplant characteristics and outcome may be derived from previously published clinical studies [18] [19] [20] and are therefore only briefly outlined in Table 1 . Homogeneity of our patient population concerning specifications of transplant-relevant characteristics is ensured by the single center study with about 80% sibling donors showing in almost 60% an identical HLA constellation with one mismatch in approximately 25% and, finally, the same conditioning regimen in more than 90% (Table 1) . Hematological reconstitution with normal graft function was assumed if patients achieved transplantderived absolute neutrophil counts greater than 0.5 × 10 9 /l and self-sustaining platelet counts greater than 20.0 × 10 9 /l by day 30 following BMT (day 0). Delayed engraftment was diagnosed if these thresholds were not reached by day 30 and graft failure was established if cell counts never reached these endpoints and were associated with extreme hypocellularity of bone marrow biopsies taken at that time. Pretransplant busulfan (BU) and hydroxyurea (HU) treatment was generally performed using conventional dosages of these agents. The majority of patients pretreated with interferon-alpha 2b (IFN-␣) had participated in different clinical trials and in none had a durable major cytogenetic remission been achieved.
Bone marrow biopsies
After informed consent had been obtained representative trephine biopsies of the bone marrow (mean size 18 × 1.2 mm) were taken from the posterior iliac crest and processed by low concentration (2-3%) formalin fixation for 3-4 days, followed by decalcification in 10% buffered ethylene-diamine tetra-acetic acid (EDTA), pH 7.2 and paraffin wax embedding. The 516 bone marrow biopsies derived from 160 patients were carried out at different times during the pre-and post-transplant periods, including a small cohort of 45 patients with initial pretreatment examinations (Table 2) . Following routine staining methods for diagnosis, Gomori's silver impregnation method for visualization of argyrophilic (reticulin-collagen) fibers was applied. Morphometric evaluation of the fiber content was performed by a manual optic planimeter (MOP-A-MO1-Kontron) with a standard program set (Kontron software, Kontron, Eching, Germany). Reticulin fibers were calcu- Table 2 Survey of sequential bone marrow examinations with regard to pre-and post-transplant periods and total fiber content (i × lated by counting the number of intersections with lines of an ocular grid at ×500 magnification and fiber density determined as the number of intersections (i) per mm 2 hematopoietic area (so-called point intersection method). To avoid the erroneous impression of a reversal of myelofibrosis due to an expansion of adipose tissue and/or interstitial edema following myeloablative radiochemotherapy and BMT, a corresponding reference to hematopoietic cellularity (ranging between 98.5 and 0%) was imperative. Because of the complex mutual functional interactions between the fibrous stromal matrix and progenitor cells, assessment of these variables seems to be reasonable, in particular when focusing on post-transplant hematopoietic reconstitution. To comply with a widely used semiquantitative scoring system of myelofibrosis 13 we additionally performed a comparative pilot study involving this grading together with the quantity of argyrophilic (reticulin) fibers determined by morphometry. Regarding the control population and our CML patients an about three-fold increase (fiber density exceeding 50 i × 10 ) was consistent with a manifest (reticulin) myelofibrosis. In addition to this more refined technique of quantifying fiber density, the significantly varying intervals between the biopsies had also to be taken into account. For this reason, the total number of 160 patients with a pretransplant biopsy were used for the assessment of engraftment parameters. On the other hand, a selected cohort of 124 patients with sequential post-transplant examinations at standardized endpoints (399 specimens) were included in the calculations of postgraft bone marrow changes (Table 2 ). In order to determine dynamic features implying progression or regression of myelofibrosis, calculations on the fiber content included a computation of differences in the degree of fiber densities. Following this rationale, a positive and high index was consistent with an advance or progression, while a negative value indicated a significant reversal of fibrosis. Bone marrow biopsies of 20 patients (nine male, 11 female; median age 42 years) without any hematological disorder served as controls.
Statistical analysis included the Mann-Whitney U test to determine possible differences of the fiber counts between the different endpoints and groups of patients examined.
Results
Dynamics of bone marrow fibrosis before and after BMT
Morphometry revealed that the mean values of fiber density were not significantly different between the pre-and posttransplant specimens. However, extreme ranges were found which needed further analysis ( Table 2) . On the other hand in 42 patients (26%), an about three-fold increase in the number of fibers compared to the control population ( Figure 1a ) was detectable before BMT. According to semiquantitative evaluation this feature implies a manifest (reticulin) fibrosis ( Figure 1b) . As has been mentioned already, the general impression of insignificant changes in the bone marrow fiber content during transplantation pro- cedures (Table 2) has to be modified in the light of more elaborate methods of calculation. Consequently, our interest was focused on more accurate information about alterations in fiber content during the peri-and post-transplant period. Following myeloablative therapy and BMT, patients with manifest myelofibrosis (Figure 1b) showed a regression within 3 months contrasting the other cohort without fibrosis (Table 3) . However, concerning long-term changes and determination of relevant dynamics, myelofibrotic patients following initial post-transplant regression later developed a definite tendency to return to more fibrotic stages in areas of regenerating hematopoiesis (Figure 1d vs  c) . This event started approximately 3 months after BMT (Table 4) . On the other hand the phenomenon of an evolving fibrosis at later endpoints was also detectable in a very few of the initially non-fibrotic patients. Development and regression of myelofibrosis at the various standardized endpoints of bone marrow examination during the pre-and post-transplant period is shown for a randomly selected patient in whom several biopsies at different intervals were performed (Figure 2) . Modalities of conditioning regimens exerted no influence on post-transplant myelofibrosis. Table 3 Fiber content (mean ± s.d., range) per mm 2 hematopoiesis in the bone marrow during the pre-and post-transplant period according to sequential biopsies (for endpoints-intervals of examination see Table 2 ). Data are shown with regard to pretransplant fibrosis, ie no fibrosis compared with manifest myelofibrosis (more than a three-fold increase in normal content of 16.2 ± 4.9 i × 10 2 /mm 2 ).
Bone marrow biopsies
Table 4
Dynamics of bone marrow fiber content (mean ± s.d., range) during peri-and post-transplant periods according to pretransplant fibrosis (for endpoints, intervals of examination see Normal range of fiber content There was also no significant impact of donor relationship (sibling or alternate) and HLA constellation on the recurrence or evolution of post-transplant myelofibrosis. Because of the various treatment combinations, concerning in particular IFN-␣ (Table 1) , the putative influence of single-agent pretransplant therapy on the development of bone marrow fibrosis was very difficult to determine. This fact may be related to the relative homogeneity of our material (Table 1) . Regarding quantity of reticulin fibers in the last bone marrow biopsies before BMT ( 
Fiber content and engraftment
When pursuing a more refined analysis of the amount and evolution of myelofibrosis before and after BMT, a delayed or failing reconstitution of hematopoiesis was significantly associated with an increase in the reticulin content of the pretransplant specimens (Table 5 ). This result has to be further specified by selecting all cases with a relevant fibrosis before BMT (Figure 1b . Moreover, patients with early to advanced myelofibrosis developing during the post-transplant period (approximately 2 to 3 months after BMT) were also characterized by a tendency for a delayed transfusion independence according to standard criteria (Table 5) . Table 5 Relationship between bone marrow reconstitution and fiber density before and after BMT (mean ± s.d., range) 
Discussion
Post-graft hematopoietic impairment may be regarded as the consequence of quantitative and qualitative alterations involving both the stem cells and the stromal compartment which are expressed as a reduced capacity of stem cell selfrenewal and commitment to differentiation into certain lineages. Therefore, it is tempting to speculate that the reticulin fiber content may be one of the factors presenting an impediment to engraftment by exerting an adverse influence on the complex functional network of the bone marrow microenvironment. For this reason, comprehensive investigations are still required to unravel progression and regression of reticulin stain -measured bone marrow fibrosis during pre-and post-transplant periods, in order to solve the problem of whether and to what extent these features may influence hematopoietic reconstitution.
1,2 In this
Bone Marrow Transplantation context, choice of pretransplant therapy was postulated to influence post-transplant outcome and, at least in some studies, IFN-␣ was associated with an unfavorable prognosis. [18] [19] [20] There have been several conflicting reports concerning an enhancing vs reducing effect of IFN-␣ on the bone marrow fiber content in CML patients. [14] [15] [16] 21 Based on sequential biopsies and following IFN-␣ monotherapy a relevant increase in fibers was detectable in the majority of patients, 15, 21 contrasting with other trials which included combination regimens with HU and Ara-C as well as significantly different intervals of examination. 14, 16 However, HU as single-agent treatment revealed a stable state or even reversal of myelofibrosis in CML patients. 21 These treatment-related alterations of myelofibrosis are also suggested in our series of patients, although the majority received IFN-␣ as combination therapy with HU. Furthermore, the significant association of manifest myelofibrosis with severe acute GVHD may exert an additional unfavorable effect. Finally, the frequency of myelofibrosis (ie a threefold and more increase in normal fiber density) in our cohort of patients should be discussed. Following various pretransplant regimens including IFN-␣ (Table 1 ) the incidence was 26% in our 160 patients and ranged from early reticulin to advanced collagen fibrosis. These data are in keeping not only with semiquantitative scoring in pretreatment bone marrow biopsies derived from large series of patients, [22] [23] [24] [25] [26] but were also supported by follow-up examinations partially including morphometry. 21, 24, 25 Methodology of quantifying myelofibrosis has to be considered, since most evaluations are based on a rather crude semiquantitative scoring which allows wide ranges of gradings in borderline lesions (initial vs early to manifest). [13] [14] [15] [16] [22] [23] [24] [25] Moreover, most scoring systems overlook the more significant problem inherent in changes in bone marrow cellularity and ensuing assessment of fibrosis. 13 Following myeloablative treatment there is a pronounced expansion of adipose tissue and considerable interstitial edema generating per se a relevant reduction of fiber density. However, concerning engraftment parameters rather than the fat cells, the areas with regenerating hematopoietic tissue deserve attention. For this reason, determination of myelofibrosis has to relate predominantly to hematopoiesis and not to the total marrow area which contains a variable amount of adipocytes and proteinaceous edema generated by transplant procedures. Additionally, one has to keep in mind that there are age-related changes in cellularity with a gradual replacement of hematopoiesis by fat tissue which ranges from 20 to 70% in the adult bone marrow. For a proper evaluation of engraftment parameters these alterations require a clear-cut reference value, ie hematopoietic cellularity for comparing different groups of patients, and concentration on areas relevant for reconstitution of marrow cells.
So far little information exists about the possible influence of pretransplant (reticulin) myelofibrosis on engraftment or outcome, because in recently published trials this feature was apparently not considered to be of any major predictive value. [27] [28] [29] [30] [31] [32] [33] [34] Contrary to findings relating an adverse effect of severe marrow fibrosis on hematopoietic recovery, 1 this result has not been confirmed in a consecutive study by the same group. 12 In this context it is imperative to mention that both studies comprised a variety of hematological malignancies besides 39 matched-related, 11 mismatched-related and nine unrelated transplants in patients with stable phase CML. 12 Altogether myelofibrosis was found to delay the time to achieve platelet transfusion independence by approximately 3 days and no other perturbation of hematopoietic reconstitution was apparent. 12 As has been explicitly discussed by the authors the failure to substantiate concerns about myelofibrosis may be influenced by the significant heterogeneity of patients entered into this study or may reflect better supportive care or even possibly less stringent criteria for diagnosis of myelofibrosis at the microscopic level. 12 In addition to the patient selection, the last point has been significantly improved in our study by including morphometric quantification of fiber density and especially by calculating this feature in relation to the amount of hematopoiesis and time (Table 4) . Finally, because myelofibrosis is consistent with a dynamic process, standardized check points should be determined as has been performed in the present evaluation by a proper amendment and computation of the raw data ( Table 2) . Regarding the previous investigations in this field, 1, 12 there is no information about the time gap between pretransplant diagnosis of myelofibrosis and data of BMT which seems to be of importance when considering this variable. A pivotal role of the bone marrow stromal constituents (microenvironment) in the regulation of hematopoiesis is a wellrecognized phenomenon 35, 36 and has been repeatedly studied in CML. [37] [38] [39] [40] In comparison to CML in idiopathic-primary myelofibrosis (IMF) allogeneic BMT was in keeping with the finding that marrow fibrosis elicited no risk factor for delayed myeloid engraftment and that myelofibrosis disappeared completely within 6 months post-transplant. 9 On the other hand, contrasting this favorable outcome, absence of osteosclerosis (endophytic woven bone formation) which is usually associated with severe collagen fibrosis 25, 41, 42 was indicative of a shorter time to reach the platelet and neutrophil engraftment endpoints in allogeneic stem cell transplantation for agnogenic myeloid metaplasia. 11 Again, complete resolution of marrow fibrosis was observed within a median period of 6 months following transplant. 11 This impression of an initial regression of fiber density following marrow-ablative regimens is generally confirmed in our group of CML patients presenting with manifest myelofibrosis before BMT, in particular when considering dynamic features in the first post-transplant months (Table 4) . Altogether, the influence of myelofibrosis on hematopoietic reconstitution in IMF needs still to be clarified, because several factors which do not apply to CML may play a crucial role. Amongst these are older age, pretransplant splenectomy and a high number of packed cell transfusions. Finally, other subtypes of chronic myeloproliferative disorders preceding agnogenic myeloid metaplasia have to be considered. 11 Considering the results derived from this study, a relevant delay could be observed in the time to reach transfusion independence and especially granulocyte recovery for patients with manifest pretransplant myelofibrosis. Following marrow-ablative therapy there was an initial regression of the reticulin fiber density. However, fibrosis showed a tendency to return insidiously during the prolonged post-transplant period in the areas of reconstituting hematopiesis.
